BioSpace News Archive

Werewolf Therapeutics, Inc. announced that it has been added to the Nasdaq Biotechnology Index, effective prior to market open on Monday, December 20, 2021.

Route 92 Medical, Inc., a private medical technology company dedicated to becoming the performance leader in stroke intervention, today announced that it has raised over $110 million in a combined Series E and debt financing.

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for XELJANZ® / XELJANZ® XR (tofacitinib) for the treatment of adults with active ankylosing spondylitis (AS) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.

Idera Pharmaceuticals, Inc. announced clinical updates regarding tilsotolimod, its synthetic Toll-like receptor 9 agonist.

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced an updated strategy for AT-527 to address the rapidly evolving SARS-CoV-2 and emerging variants by maximizing the compound’s unique profile for potential use as both a monotherapy and in combination.

Svelte Medical Systems received U.S. Food and Drug Administration (FDA) approval to commercialize the SLENDER IDS® fixed-wire and DIRECT RX® rapid-exchange drug-eluting stent (DES) systems for the treatment of coronary artery disease in the U.S. SLENDER IDS® and DIRECT RX®.

Growing use of carotenoids as natural food colorants, growing number of experimental studies to explore anti-cancer activity of carotenoids, and increasing consumption of dietary carotenoids due to health benefits are some key factors expected to drive market growth.

AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today provided a status update on its expansion of key patent applications into several major ex-US territories worldwide.

Biognosys, and Thermo Fisher Scientific, announced today that they have extended a co-marketing agreement to provide life science researchers with comprehensive mass spectrometry solutions to gain deep proteomics insights at a large scale.

Growing geriatric population and increasing molecular, pathological, and immunological tests are expected to bolster market growth.